Paroxysmal Nocturnal Hemoglobinuria (PNH) and IgA nephropathy (IgAN) research hub

An open-label, single-arm, multicenter roll-over extension program (REP) to characterize the long-term safety and tolerability of iptacopan (LNP023) in patients who have completed a clinical trial (parent study) in the iptacopan pediatric program.

This study looks at the long-term safety of a medicine called iptacopan. It is designed for children and young people who have already completed an earlier trial for iptacopan to treat either paroxysmal nocturnal haemoglobinuria (a rare blood condition) or IgA nephropathy (a kidney disease).